Epigenetic regulatory enzymes are generally considered innovative targets for cancer therapy and several histone methyltransferase inhibitors are currently being evaluated in phase I and phase II clinical trials. In this commentary, we discuss the need for better functional understanding of histone methyltransferases and especially of their potential non-histone substrates.
This is a preview of subscription content, log in via an institution to check access.
References
Choudhary, C. et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325, 834–840 (2009).
Audia, J. E. & Campbell, R. M. Histone modifications and cancer. Cold Spring Harb. Perspect. Biol. 8, a019521 (2016).
Carlson, S. M. & Gozani, O. Nonhistone lysine methylation in the regulation of cancer pathways. Cold Spring Harb. Perspect. Med. 6, a026435 (2016).
Buuh, Z. Y., Lyu, Z. & Wang, R. E. Interrogating the roles of post-translational modifications of non-histone proteins. J. Med. Chem. 61, 3239–3252 (2018).
Copeland, R. A. Protein methyltransferase inhibitors as precision cancer therapeutics: a decade of discovery. Phil. Trans. R. Soc. B 373, 20170080 (2018).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Rodríguez-Paredes, M., Lyko, F. The importance of non-histone protein methylation in cancer therapy. Nat Rev Mol Cell Biol 20, 569–570 (2019). https://doi.org/10.1038/s41580-019-0147-x
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41580-019-0147-x
- Springer Nature Limited
This article is cited by
-
Epigenetic modification of m6A regulator proteins in cancer
Molecular Cancer (2023)
-
Targeting epigenetic and posttranslational modifications regulating ferroptosis for the treatment of diseases
Signal Transduction and Targeted Therapy (2023)
-
PRMT5 methylating SMAD4 activates TGF-β signaling and promotes colorectal cancer metastasis
Oncogene (2023)
-
Control of protein stability by post-translational modifications
Nature Communications (2023)
-
High-affinity chromodomains engineered for improved detection of histone methylation and enhanced CRISPR-based gene repression
Nature Communications (2022)